Total Payments
$179,660
2024 Payments
$137,792
Companies
18
Transactions
295
Medicare Patients
1,228
Medicare Billing
$125,197
Payment Breakdown by Category
Other$140,950 (78.5%)
Travel$21,533 (12.0%)
Research$7,281 (4.1%)
Food & Beverage$7,016 (3.9%)
Consulting$2,778 (1.5%)
Education$102.09 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $140,950 | 51 | 78.5% |
| Travel and Lodging | $21,533 | 69 | 12.0% |
| Unspecified | $7,281 | 6 | 4.1% |
| Food and Beverage | $7,016 | 164 | 3.9% |
| Consulting Fee | $2,778 | 3 | 1.5% |
| Education | $102.09 | 2 | 0.1% |
Payments by Type
General
$172,379
289 transactions
Research
$7,281
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $93,889 | 131 | $0 (2024) |
| Lilly USA, LLC | $73,358 | 94 | $0 (2024) |
| Eli Lilly and Company | $7,281 | 6 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $1,888 | 6 | $0 (2024) |
| Celgene Corporation | $1,738 | 19 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $495.82 | 17 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $252.83 | 3 | $0 (2023) |
| Janssen Biotech, Inc. | $250.26 | 6 | $0 (2024) |
| Olympus America Inc. | $103.70 | 4 | $0 (2024) |
| Covidien LP | $94.04 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $137,792 | 173 | ABBVIE INC. ($72,724) |
| 2023 | $31,887 | 81 | AbbVie Inc. ($20,725) |
| 2022 | $590.53 | 18 | ABBVIE INC. ($326.11) |
| 2021 | $5,063 | 4 | Eli Lilly and Company ($5,001) |
| 2019 | $1,909 | 6 | Eli Lilly and Company ($1,625) |
| 2018 | $2,342 | 12 | Celgene Corporation ($1,541) |
| 2017 | $75.13 | 1 | Gilead Sciences Inc ($75.13) |
All Payment Transactions
295 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $109.72 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $56.14 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $32.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $21.24 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $10.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: Immunology | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,875.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | Olympus America Inc. | VISIGLIDE (Device) | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: Endotherapy | ||||||
| 11/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | Lilly USA, LLC | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Lilly USA, LLC | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $370.80 | General |
| 11/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $50.97 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $9.25 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $40.92 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $11.91 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/08/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $91.21 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $575.00 | General |
| 11/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $556.62 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $432.46 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $4,253 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $3,019 | 2 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $9.15 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 72 | 78 | $95,349 | $9,569 |
| 2022 | 10 | 358 | 386 | $129,494 | $36,132 |
| 2021 | 12 | 390 | 424 | $128,400 | $41,134 |
| 2020 | 10 | 408 | 443 | $121,940 | $38,361 |
Total Patients
1,228
Total Services
1,331
Medicare Billing
$125,197
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 20 | 21 | $45,021 | $4,038 | 9.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 15 | $9,885 | $1,869 | 18.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 15 | 19 | $3,127 | $1,801 | 57.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $19,316 | $972.21 | 5.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $18,000 | $888.95 | 4.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 65 | 65 | $42,609 | $11,479 | 26.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 77 | 78 | $16,562 | $8,002 | 48.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 61 | 62 | $26,190 | $3,846 | 14.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 47 | 66 | $7,410 | $3,461 | 46.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 29 | 29 | $16,681 | $2,582 | 15.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $5,993 | $2,092 | 34.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 25 | 29 | $3,090 | $1,820 | 58.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 15 | 18 | $2,738 | $1,572 | 57.4% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2022 | 11 | 11 | $7,381 | $905.31 | 12.3% |
| 99451 | Telephone or internet assessment with written report by consulting physician, 5 minutes or more | Facility | 2022 | 14 | 14 | $840.00 | $371.22 | 44.2% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 61 | 61 | $38,796 | $12,074 | 31.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 59 | 62 | $12,958 | $6,505 | 50.2% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 67 | 69 | $24,583 | $4,653 | 18.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 52 | 74 | $8,214 | $4,132 | 50.3% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 40 | 40 | $21,360 | $3,578 | 16.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 38 | 44 | $4,668 | $3,187 | 68.3% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 11 | 11 | $4,917 | $1,643 | 33.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 14 | $1,932 | $1,546 | 80.0% |
| 43248 | Insertion of guide wire with dilation of esophagus using an endoscope | Facility | 2021 | 12 | 12 | $4,620 | $1,160 | 25.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 11 | 11 | $1,832 | $1,081 | 59.0% |
About Dr. Maithili Chitnavis, MD
Dr. Maithili Chitnavis, MD is a Gastroenterology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2011. The National Provider Identifier (NPI) number assigned to this provider is 1720378730.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Maithili Chitnavis, MD has received a total of $179,660 in payments from pharmaceutical and medical device companies, with $137,792 received in 2024. These payments were reported across 295 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($140,950).
As a Medicare-enrolled provider, Chitnavis has provided services to 1,228 Medicare beneficiaries, totaling 1,331 services with total Medicare billing of $125,197. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Internal Medicine
- Location Charlotte, NC
- Active Since 04/11/2011
- Last Updated 07/15/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1720378730
Products in Payments
- SKYRIZI (Biological) $66,176
- OMVOH (Drug) $57,512
- RINVOQ (Biological) $20,497
- TREMFYA (Drug) $1,688
- Ozanimod (Drug) $1,541
- STELARA (Biological) $450.13
- ENTYVIO (Biological) $418.76
- ZEPOSIA (Drug) $379.65
- Mavyret (Drug) $112.90
- Beacon (Device) $94.04
- Epclusa (Drug) $75.13
- VISIGLIDE (Device) $69.60
- Doptelet (Drug) $68.40
- INJECTAFER (Drug) $52.00
- GI GENIUS (Device) $44.33
- Olympus (Device) $34.10
- HUMIRA (Biological) $26.24
- Entyvio (Biological) $18.08
- Flexitouch Plus (Device) $16.74
- LYNPARZA (Drug) $16.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Charlotte
Stephen Deal, M.d, M.D
Gastroenterology — Payments: $1.3M
Gastroenterology $1.3M
Fred Fowler, M.d, M.D
Gastroenterology — Payments: $873,591
Gastroenterology $873,591
Nilesh Lodhia, Md, MD
Gastroenterology — Payments: $807,140
Gastroenterology $807,140
Oscar Brann, M.d, M.D
Gastroenterology — Payments: $246,482
Gastroenterology $246,482
Dr. Kent Holtzmuller, Md, MD
Gastroenterology — Payments: $160,162
Gastroenterology $160,162
Ronnie Cyzner, M.d, M.D
Gastroenterology — Payments: $78,895
Gastroenterology $78,895